Microbot Medical CMO awarded 105,000 stock options

Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.

Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.

Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.

Insider Trade Summary

Grant/Award: 105,000 shares

Grant/Award 1 txn

Insider Diaz-Cartelle Juan

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	105,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 105,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.

FAQ

What insider transaction did Microbot Medical (MBOT) report on this Form 4?

Microbot Medical reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options for 105,000 shares. The options were awarded at no cost under the company’s 2020 Omnibus Performance Award Plan, reflecting equity-based executive compensation.

How many stock options did MBOT’s Chief Medical Officer receive?

MBOT’s Chief Medical Officer received stock options covering 105,000 shares of common stock. This entire amount was reported as held after the transaction, indicating a new grant rather than a sale or purchase of existing shares in the open market.

What is the vesting schedule for the 105,000 stock options at Microbot Medical?

The options vest in stages. On August 18, 2026, 25% of the 105,000-share grant becomes exercisable. The remaining 75% then vests in equal quarterly installments over the next 30 months, following the company’s 2020 Omnibus Performance Award Plan terms.

Was this MBOT Form 4 transaction a purchase or a sale of shares?

The Form 4 reports an acquisition through a stock option grant, not a market purchase or sale. It is classified as a grant, award, or other acquisition, with no shares sold and no open-market buying activity disclosed in this particular filing.

Are the newly granted MBOT stock options immediately exercisable by the CMO?

No, the stock options are not fully exercisable immediately. Only 25% will vest and become exercisable on August 18, 2026, and the remaining 75% will vest quarterly over 30 months, with vesting subject to potential acceleration or forfeiture under plan rules.

Under which plan were the 105,000 MBOT stock options granted?

The options were granted under Microbot Medical’s 2020 Omnibus Performance Award Plan, as amended. This plan governs vesting, exercisability, and conditions such as potential acceleration or forfeiture, making it the framework for the Chief Medical Officer’s equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Diaz-Cartelle Juan

(Last) (First) (Middle)

C/O MICROBOT MEDICAL INC.

175 DERBY ST., BLD. 27

(Street)

HINGHAM MA 02043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Microbot Medical Inc. [ MBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.1	02/18/2026		A		105,000		(1)	02/18/2036	Common Stock, par value $0.01 per share	105,000	$0	105,000	D

Explanation of Responses:

1. The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.

	/s/ Juan Diaz-Cartelle	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.